Literature DB >> 23352352

Long-term survival of patients with glioblastoma multiforme (GBM).

Nicolas R Smoll1, Karl Schaller, Oliver P Gautschi.   

Abstract

Long-term survival is an often used, yet poorly defined, concept in the study of glioblastoma multiforme (GBM). This study suggests a method to define a time-point for long-term survival in patients with GBM. Data for this study were obtained from the Surveillance, Epidemiology and End-Results database, which was limited to the most recent data using the period approach. Relative survival measures were used and modelled using piecewise constant hazards to describe the survival profile of long-term survivors of GBM. For patients with GBM, the first quarter of the second year (5th quarter) post-diagnosis is considered to be the peak incidence of mortality with an excess hazard ratio of 7.58 (95% confidence interval=6.54, 8.78) and the risk of death due to GBM decreases to half of its rate at 2.5 years post-diagnosis. The 2.5-year cumulative relative survival (CRS) for all patients is approximately 8%, with a CRS of approximately 2% at 10 years. Using the definition of long-term survival suggested here, the results indicate that long-term survivors are patients who survive at least 2.5 years post-diagnosis. The most likely time period for patients with GBM to die is the 5th quarter post-diagnosis.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23352352     DOI: 10.1016/j.jocn.2012.05.040

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  44 in total

1.  Increased expression of the 58-kD microspherule protein (MSP58) is correlated with poor prognosis in glioma patients.

Authors:  Wei Lin; Xiao-Ming Li; Jing Zhang; Yi Huang; Jiang Wang; Jian Zhang; Xiao-Fan Jiang; Zhou Fei
Journal:  Med Oncol       Date:  2013-08-31       Impact factor: 3.064

2.  Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival.

Authors:  Susann Herzog; Matthias Alexander Fink; Kerstin Weitmann; Claudius Friedel; Stefan Hadlich; Sönke Langner; Katharina Kindermann; Tobias Holm; Andreas Böhm; Eskil Eskilsson; Hrvoje Miletic; Markus Hildner; Michael Fritsch; Silke Vogelgesang; Christoph Havemann; Christoph Alexander Ritter; Henriette Elisabeth Meyer zu Schwabedissen; Bernhard Rauch; Wolfgang Hoffmann; Heyo Klaus Kroemer; Henry Schroeder; Sandra Bien-Möller
Journal:  Neuro Oncol       Date:  2014-08-25       Impact factor: 12.300

Review 3.  Life beyond a diagnosis of glioblastoma: a systematic review of the literature.

Authors:  L Gately; S A McLachlan; A Dowling; J Philip
Journal:  J Cancer Surviv       Date:  2017-02-13       Impact factor: 4.442

4.  Relationship between Glioblastoma Heterogeneity and Survival Time: An MR Imaging Texture Analysis.

Authors:  Y Liu; X Xu; L Yin; X Zhang; L Li; H Lu
Journal:  AJNR Am J Neuroradiol       Date:  2017-06-29       Impact factor: 3.825

5.  Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.

Authors:  Bryan D Choi; Carter M Suryadevara; Patrick C Gedeon; James E Herndon; Luis Sanchez-Perez; Darell D Bigner; John H Sampson
Journal:  J Clin Neurosci       Date:  2013-09-17       Impact factor: 1.961

6.  Characteristics and survival outcomes associated with the lack of radiation in the treatment of glioblastoma.

Authors:  Bin Huang; Therese A Dolecek; Quan Chen; Catherine R Garcia; Thomas Pittman; John L Villano
Journal:  Med Oncol       Date:  2018-04-17       Impact factor: 3.064

7.  Glioma-derived extracellular vesicles selectively suppress immune responses.

Authors:  Justin E Hellwinkel; Jasmina S Redzic; Tessa A Harland; Dicle Gunaydin; Thomas J Anchordoquy; Michael W Graner
Journal:  Neuro Oncol       Date:  2015-09-18       Impact factor: 12.300

8.  Predicting distress among people who care for patients living longer with high-grade malignant glioma.

Authors:  B Russell; A Collins; A Dowling; M Dally; M Gold; M Murphy; J Burchell; J Philip
Journal:  Support Care Cancer       Date:  2015-04-25       Impact factor: 3.603

Review 9.  Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies.

Authors:  Barbara R Tschida; David A Largaespada; Vincent W Keng
Journal:  Semin Cell Dev Biol       Date:  2014-01-24       Impact factor: 7.727

10.  Feasibility study of brain tumor delineation using immunolabeled gold nanorods.

Authors:  Kevin Seekell; Spencer Lewis; Christy Wilson; Shuqin Li; Gerald Grant; Adam Wax
Journal:  Biomed Opt Express       Date:  2013-10-01       Impact factor: 3.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.